‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

October 13, 2026

•

15:17 UTC

•

Target Assets:#MARKET

Executive AI Takeaway

‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks — Market signal: BULLISH (medium Impact)

The controversial investor has been weighing in on biopharma stocks even though he’s banned from doing so.

Direct Market Tools

Direct Publisher Feed

Original report published by MarketWatch.